Preliminary proteomicsanalysis of the potential use of hmgb1 as sepsis biomarker

  1. Laura de la Cruz Martínez-Leal
  2. Concepción Garcés
  3. José Luis GarcíaGiménez
  4. Federico V. Pallardó
  5. Carlos Romá-Mateo
Buch:
Investigaciones DACIU 2022-2023: Una publicación que refleja los trabajos realizados por los participantes en el programa DACIU en su primera edición

Verlag: Fundación Avanza

ISBN: 978-84-09-50462-6

Datum der Publikation: 2023

Seiten: 559-562

Art: Buch-Kapitel

DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Zusammenfassung

Sepsis is known to be the first cause for death from infection cases. Predicting the advance of thedisease in a patient would help to develop more specified treatments that could help to reducethe high rates of mortality linked to this complex illness, especially when it progresses to septicshock. The actual biomarkers used to know the patient’s condition require a lot of resourcesand are rarely translated into the clinical practice. With this study, we evaluate the first stepsinto the development of a new possible biomarker consisting in detection of the presence of theprotein HGMB1 in plasma, using targeted mass spectrometry (Multiple-Reaction-MonitoringMS, MRM-MS) as it has been observed that it is released into the bloodstream of sepsis patients.

Fuente de los datos: Dialnet